Buckle Therapeutics
Buckle Therapeutics is transforming how people access and administer medications by delivering them directly through the cheek — fast, simple, and needle-free. Our platform is designed to support individuals across a wide range of conditions where traditional delivery methods may be impractical, inaccessible, or unwanted.
Overview
Delivering medicine without needles directly to the bloodstream when every second counts.
Buckle Therapeutics's Mission
Buckle Therapeutics is a medication delivery company reimagining how drugs reach the bloodstream. Using a patented applicator and formulation system, Buckle’s platform delivers medication through the inner cheek, bypassing the need for swallowing, inhaling, or injecting. This approach opens new possibilities for use in pediatric care, acute symptom relief, allergic reactions, and poisoning reversal — particularly for individuals who are incapacitated, needle-averse, or unable to self-administer. With no patient repositioning or setup required, our technology aims to reduce the complexity and delay often associated with conventional medication formats.
Beyond the first product, Buckle’s long-term vision is to build a versatile platform that supports a broad set of therapeutic categories. Our buccal delivery system is designed for regulatory efficiency, leveraging established pathways for drug approval, while maintaining a high degree of flexibility in formulation and design. We believe that improved delivery can expand access, empower caregivers, and reduce friction in high-need moments — creating value across clinical and consumer settings alike.
At-a-Glance
Needle-free platform for systemic drug delivery: Buckle’s single-use applicator delivers medication via the cheek for rapid bloodstream absorption, without injections, swallowing, or inhalation. Designed for use in real-world conditions where traditional formats may fall short.
Lead program: Buccal naloxone for opioid poisoning reversal: Our first product is in development for use in fentanyl and opioid poisoning scenarios. It is being evaluated through a streamlined FDA pathway with a focus on real-world usability and scalable manufacturing.
Scalable pipeline addressing multiple use cases: Future programs include expansion into anti-anxiety, geriatric, and procedural care. Plus, co-development opportunities for biotech and pharma partners who are having trouble with liver toxicity, gastrointestinal side effects and/or speed of onset for their molecules.
